5th Nordic RWE and AI conference, 28-29 January 2025, Helsinki is organized by University of Helsinki and Åbo Akademi University. This conference is supported by NordicPOP, NordicPharmaTrain and European Federation for Pharmaceutical Industries and Associations Efpia. The Company sponsors listed in the Program have enabled us to organize the Event free of charge on Site and the City of Helsinki enables a nice Networking Event in the Evening. A warm thank you to all.
Program:
Implementation of EHDS – how to improve the competitiveness of the Nordic Region
- TEHDAS2 and VALO Value from Nordic health data – VALO – Sitra Markus Kalliola, Program Director, Coordinator of Joint Action Towards TEHDAS 2 and VALO projects
- European Health Data Space – a stealth revolution. Richard Bergström, Vice President European Affairs, IQVIA
- Secure Processing Environment (SPE) – Your Gateway from Individual Level RWD to RWE. Erkki Soini. CEO, ESiOR Oy. Chairman on the Board, Kuopio Health
- The global value of Nordic data – selected use cases. Emilie Toresson Grip, QuantifyResearch
- Focus on the key comparative advantages of the Nordic RWD landscape, compared to other US/EU RWD assets. Illustrate the key strengths of pan-Nordic research in collaboration with global pharma stakeholders, including Nordic data contributions to international, multi-country studies.
- Nordic data landscape today and tomorrow. Nordic Healthcare Group
- RWE in value-based healthcare.
- How will Regulators, HTA bodies, and Payers use of RWD and AI for assessment and approval as well for improving healthcare/treatment outcomes of medicine.
- Building a Foundation for Evidence-Based Healthcare: The Impact of Real-Time Data in clinical decision making, Real-World Evidence Generation and on building Registries. Joakim Söderberg, Head of Business Development, BCB Medical
- Hospital payer perspective: what RWD is needed to secure adaptation of new oncology treatments. Sami Pakarinen, Chief Medical Officer of Clinical Auditing at HUCH.
- Electronic health records, natural language processing models, and lung cancer outcomes. MedAffcon
How will broad use of RWD and AI change Drug discovery and development and will the use of data improve the competitiveness of EU in R&D and result in science as well as value based decision making and healthcare
- The power of combining Norwegian healthdata and AI: A case example from Novartis and Akershus University Hospital. Novartis
- Transforming Clinical Trial Practices through Real-World Data. Tero Ylisaukko-oja, CEO, founder, MedEngine Oy
- Real-world data (RWD) have great potential to revolutionize clinical development, particularly in rare diseases. By leveraging RWD in natural history studies, researchers can gain valuable insights into disease progression and identify key factors—such as demographic, genetic, and environmental influences—that shape patient outcomes under current standards of care. These insights are crucial for designing clinical trials with optimal duration, meaningful endpoints, and the possibility of incorporating external control arms. Data from the Nordic countries provide a uniquely robust foundation for conducting these transformative studies.
We thank our supporters!
